{"protocolSection": {"identificationModule": {"nctId": "NCT00415623", "orgStudyIdInfo": {"id": "A0531085"}, "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient", "officialTitle": "A Double-Blind, Comparative Study Between Amlodipine 5mg And 10mg In Patients With Essential Hypertension For Whom Amlodipine 5mg Is Insufficiently Effective"}, "statusModule": {"statusVerifiedDate": "2021-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-01"}, "primaryCompletionDateStruct": {"date": "2007-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-12-21", "studyFirstSubmitQcDate": "2006-12-22", "studyFirstPostDateStruct": {"date": "2006-12-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2008-10-16", "resultsFirstSubmitQcDate": "2008-12-05", "resultsFirstPostDateStruct": {"date": "2008-12-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-01-26", "lastUpdatePostDateStruct": {"date": "2021-02-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The changes in the trough systolic blood pressure from the baseline were assessed after 8 weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg"}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 305, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Amlodipine 5mg", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Amlodipine"]}, {"label": "Amlodipine 10mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Amlodipine"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine", "description": "Amlodipine 5mg/ day", "armGroupLabels": ["Amlodipine 5mg"]}, {"type": "DRUG", "name": "Amlodipine", "description": "Amlodipine 10mg/ day", "armGroupLabels": ["Amlodipine 10mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Systolic Blood Pressure (SBP) From Baseline to Week 8", "description": "Mean change in the trough SBP", "timeFrame": "Baseline to Week 8"}], "secondaryOutcomes": [{"measure": "Change in Diastolic Blood Pressure (DBP) From Baseline to Week 8", "description": "Mean change in the trough DBP", "timeFrame": "Baseline to Week 8"}, {"measure": "Combined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient)", "description": "Arithmetic mean of Week 6 \\& Week 8 by patient for \"Change from baseline in SBP at Week 6\" and \"Change from baseline in SBP at Week 8\"", "timeFrame": "Baseline to Week 6 and Week 8"}, {"measure": "Combined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient)", "description": "Arithmetic mean of Week 6 \\& Week 8 by patient for \"Change from baseline in DBP at Week 6\" and \"Change from baseline in DBP at Week 8\"", "timeFrame": "Baseline to Week 6 and Week 8"}, {"measure": "Number of Subjects Achieving the Target Blood Pressure Reduction Value at Week 8", "description": "Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \\<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \\>=65 years old", "timeFrame": "Week 8"}, {"measure": "Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 8", "description": "Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \\<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \\>=65 years old", "timeFrame": "Week 6 and Week 8"}, {"measure": "Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Week 8", "description": "Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \\<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \\>=65 years old", "timeFrame": "Week 8"}, {"measure": "Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Both Weeks 6 and 8", "description": "Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \\<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \\>=65 years old", "timeFrame": "Week 6 and Week 8"}, {"measure": "Trough Plasma Concentrations of Amlodipine -Amlodipine 5 mg", "timeFrame": "Baseline, Week 4 and Week 8"}, {"measure": "Trough Plasma Concentrations of Amlodipine -Amlodipine 10 mg", "timeFrame": "Baseline, Week 4, and Week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Untreated Hypertensive Patients: An systolic blood pressure of \\>=160 mmHg or diastolic blood pressure \\>=100mmHg.\n* Treated Hypertensive Patients: An systolic blood pressure of \\>=140 mmHg or diastolic blood pressure of \\>= 90 mmHg.\n* Patients with insufficient response to 5 mg of amlodipine in the screening period:Two successive systolic blood pressure measurements at Visit 4 (Week -2) and Visit 5 (Week 0 = baseline) \\>=140 mmHg\n* Patients with a screening treatment compliance rate \\>= 80%\n\nExclusion Criteria:\n\n* Subjects with secondary hypertension (renal disease, pheochromocytoma, and Cushing's syndrome, etc.), severe hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic blood pressure of 110 mmHg or higher), and malignant hypertension", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Pfizer Investigational Site", "city": "Kasuya-gun", "state": "Fujuoka", "country": "Japan", "geoPoint": {"lat": 35.66253, "lon": 139.60746}}, {"facility": "Pfizer Investigational Site", "city": "Chikushino", "state": "Fukuoka", "country": "Japan", "geoPoint": {"lat": 33.49631, "lon": 130.5156}}, {"facility": "Pfizer Investigational Site", "city": "Kitakyushu", "state": "Fukuoka", "country": "Japan", "geoPoint": {"lat": 33.85181, "lon": 130.85034}}, {"facility": "Pfizer Investigational Site", "city": "Koga", "state": "Fukuoka", "country": "Japan", "geoPoint": {"lat": 33.73333, "lon": 130.46667}}, {"facility": "Pfizer Investigational Site", "city": "Sapporo", "state": "Hokkaidou", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Pfizer Investigational Site", "city": "Sapporo", "state": "Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Pfizer Investigational Site", "city": "Yokohama", "state": "Kanagawa", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Pfizer Investigational Site", "city": "Iruma", "state": "Saitama", "country": "Japan"}, {"facility": "Pfizer Investigational Site", "city": "Koshigaya", "state": "Saitama", "country": "Japan", "geoPoint": {"lat": 35.89035, "lon": 139.78916}}, {"facility": "Pfizer Investigational Site", "city": "Adachi-ku", "state": "Tokyo", "country": "Japan"}, {"facility": "Pfizer Investigational Site", "city": "Edogawa-ku", "state": "Tokyo", "country": "Japan"}, {"facility": "Pfizer Investigational Site", "city": "Meguro-ku", "state": "Tokyo", "country": "Japan", "geoPoint": {"lat": 42.12755, "lon": 143.31736}}, {"facility": "Pfizer Investigational Site", "city": "Setagaya-ku", "state": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.64825, "lon": 139.65376}}, {"facility": "Pfizer Investigational Site", "city": "Sumida", "state": "Tokyo", "country": "Japan"}, {"facility": "Pfizer Investigational Site", "city": "Fukuoka", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0531085&StudyName=A%20Comparative%20Study%20Between%20Amlodipine%2010mg%20And%205mg%20With%20Hypertension%20For%20Whom%205mg%20Is%20Insufficient"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Consent was taken from 414 patients, 356 patients who met the screening criteria received amlodipine 5 mg. After the 8 weeks of screening treatment, patients who met the entry criteria for double-blind period were randomized to either the amlodipine 10 mg group or the amlodipine 5 mg group at a ratio of 1:1.", "recruitmentDetails": "Twenty-four (24) centers in Japan", "groups": [{"id": "FG000", "title": "Amlodipine 5 mg", "description": "One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks."}, {"id": "FG001", "title": "Amlodipine 10 mg", "description": "Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "154"}, {"groupId": "FG001", "numSubjects": "151"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "149"}, {"groupId": "FG001", "numSubjects": "146"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Amlodipine 5 mg", "description": "One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks."}, {"id": "BG001", "title": "Amlodipine 10 mg", "description": "Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "154"}, {"groupId": "BG001", "value": "151"}, {"groupId": "BG002", "value": "305"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "partcipants", "classes": [{"title": "< 20 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "20 to 44 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "30"}]}]}, {"title": "45 to 64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "75"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "145"}]}]}, {"title": ">= 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "66"}, {"groupId": "BG002", "value": "130"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "70"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "129"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "176"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Japan", "categories": [{"measurements": [{"groupId": "BG000", "value": "154"}, {"groupId": "BG001", "value": "151"}, {"groupId": "BG002", "value": "305"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Systolic Blood Pressure (SBP) From Baseline to Week 8", "description": "Mean change in the trough SBP", "populationDescription": "Full Analysis Set, Last Observation Carried Forward", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 8", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.0", "lowerLimit": "-8.8", "upperLimit": "-5.2"}, {"groupId": "OG001", "value": "-13.7", "lowerLimit": "-15.4", "upperLimit": "-12.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). ANCOVA models with the trough SBP at baseline, body weight, and age as covariates, and the treatment group and study site as factors was used. The test was performed with a significance level of 0.05 (two-sided).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.7", "ciPctValue": "95", "ciLowerLimit": "-9.0", "ciUpperLimit": "-4.4"}]}, {"type": "SECONDARY", "title": "Change in Diastolic Blood Pressure (DBP) From Baseline to Week 8", "description": "Mean change in the trough DBP", "populationDescription": "Full Analysis Set, Last Observation Carried Forward", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 8", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.7", "lowerLimit": "-3.9", "upperLimit": "-1.4"}, {"groupId": "OG001", "value": "-6.8", "lowerLimit": "-8.0", "upperLimit": "-5.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). ANCOVA models with the trough DBP at baseline, body weight, and age as covariates, and the treatment group and study site as factors was used. The test was performed with a significance level of 0.05 (two-sided).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-4.1", "ciPctValue": "95", "ciLowerLimit": "-5.7", "ciUpperLimit": "-2.5"}]}, {"type": "SECONDARY", "title": "Combined Mean Change in SBP From Baseline to Week 6 and Week 8 (Mean by Patient)", "description": "Arithmetic mean of Week 6 \\& Week 8 by patient for \"Change from baseline in SBP at Week 6\" and \"Change from baseline in SBP at Week 8\"", "populationDescription": "Full Analysis Set, Last Observation Carried Forward", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 6 and Week 8", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.8", "lowerLimit": "-8.4", "upperLimit": "-5.2"}, {"groupId": "OG001", "value": "-13.9", "lowerLimit": "-15.5", "upperLimit": "-12.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). ANCOVA models with the trough SBP at baseline, body weight, and age as covariates, and the treatment group and study site as factors was used. The test was performed with a significance level of 0.05 (two-sided).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.1", "ciPctValue": "95", "ciLowerLimit": "-9.1", "ciUpperLimit": "-5.1"}]}, {"type": "SECONDARY", "title": "Combined Mean Change in DBP From Baseline to Week 6 and Week 8 (Mean by Patient)", "description": "Arithmetic mean of Week 6 \\& Week 8 by patient for \"Change from baseline in DBP at Week 6\" and \"Change from baseline in DBP at Week 8\"", "populationDescription": "Full Analysis Set, Last Observation Carried Forward", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 6 and Week 8", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.5", "lowerLimit": "-3.6", "upperLimit": "-1.4"}, {"groupId": "OG001", "value": "-6.5", "lowerLimit": "-7.6", "upperLimit": "-5.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). ANCOVA models with the trough DBP at baseline, body weight, and age as covariates, and the treatment group and study site as factors was used. The test was performed with a significance level of 0.05 (two-sided).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-4.0", "ciPctValue": "95", "ciLowerLimit": "-5.4", "ciUpperLimit": "-2.6"}]}, {"type": "SECONDARY", "title": "Number of Subjects Achieving the Target Blood Pressure Reduction Value at Week 8", "description": "Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \\<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \\>=65 years old", "populationDescription": "Full Analysis Set, Last Observation Carried Forward", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Proportions of participants (responder rates) were used for the statistical analyses. The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). The test was conducted based on a logistic regression model with baseline SBP value and body weight as covariates, and treatment group and age (\\<=64, \\>=65) as a factor. The significance level was 0.05 (two-sided).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.002", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.33", "ciPctValue": "95", "ciLowerLimit": "1.36", "ciUpperLimit": "3.99"}]}, {"type": "SECONDARY", "title": "Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value at Both Weeks 6 and 8", "description": "Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \\<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \\>=65 years old", "populationDescription": "Full Analysis Set, Last Observation Carried Forward", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 6 and Week 8", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "52"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Proportions of participants (responder rates) were used for the statistical analyses. The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). The test was conducted based on a logistic regression model with baseline SBP value and body weight as covariates, and treatment group and age (\\<=64, \\>=65) as a factor. The significance level was 0.05 (two-sided).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "4.46", "ciPctValue": "95", "ciLowerLimit": "2.28", "ciUpperLimit": "8.74"}]}, {"type": "SECONDARY", "title": "Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Week 8", "description": "Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \\<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \\>=65 years old", "populationDescription": "Full Analysis Set, Last Observation Carried Forward", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "61"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Proportions of participants (responder rates) were used for the statistical analyses. The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). The test was conducted based on a logistic regression model with baseline SBP value and body weight as covariates, and treatment group and age (\\<=64, \\>=65) as a factor. The significance level was 0.05 (two-sided).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.001", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.55", "ciPctValue": "95", "ciLowerLimit": "1.50", "ciUpperLimit": "4.36"}]}, {"type": "SECONDARY", "title": "Combined Number of Subjects Achieving the Target Blood Pressure Reduction Value and Whose SBP Decreased From Baseline by >= 10 mmHg at Both Weeks 6 and 8", "description": "Target blood pressure reduction value based on Japan Society of Hypertension Guidelines for the Management of Hypertension 2004: SBP below 130 mmHg and DBP below 85 mmHg for \\<=64 years old; SBP below 140 mmHg and DBP below 90 mmHg for \\>=65 years old", "populationDescription": "Full Analysis Set, Last Observation Carried Forward", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 6 and Week 8", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg", "description": "One amlodipine besilate 5 mg tablet and 1 amlodipine besilate 5 mg placebo tablet were administered once daily after breakfast for 8 weeks."}, {"id": "OG001", "title": "Amlodipine 10 mg", "description": "Two amlodipine besilate 5 mg tablets were administered once daily after breakfast for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "44"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Proportions of participants (responder rates) were used for the statistical analyses. The hypothesis of no group differences (null hypothesis) was tested against that of the amlodipine 10 mg arm being superior to the amlodipine 5 mg arm (alternative hypothesis). The test was conducted based on a logistic regression model with baseline SBP value and body weight as covariates, and treatment group and age (\\<=64, \\>=65) as a factor. The significance level was 0.05 (two-sided).", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "4.16", "ciPctValue": "95", "ciLowerLimit": "2.12", "ciUpperLimit": "8.19"}]}, {"type": "SECONDARY", "title": "Trough Plasma Concentrations of Amlodipine -Amlodipine 5 mg", "populationDescription": "Plasma concentration obtained after temporarily dosing discontinuation or not matched with the following conditions were excluded from the analysis; Steady-state condition: at least 80% drug compliance from the previous visit to the day of sampling; Trough condition: samples taken within \u00b110% of 24 hours from last dosing.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline, Week 4 and Week 8", "groups": [{"id": "OG000", "title": "Baseline", "description": "After once daily administration of amlodipine 5 mg for 8 weeks in the screening period"}, {"id": "OG001", "title": "Week 4"}, {"id": "OG002", "title": "Week 8"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "146"}, {"groupId": "OG002", "value": "145"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.02", "lowerLimit": "6.5", "upperLimit": "7.5"}, {"groupId": "OG001", "value": "6.83", "lowerLimit": "6.3", "upperLimit": "7.4"}, {"groupId": "OG002", "value": "7.03", "lowerLimit": "6.6", "upperLimit": "7.5"}]}]}]}, {"type": "SECONDARY", "title": "Trough Plasma Concentrations of Amlodipine -Amlodipine 10 mg", "populationDescription": "Plasma concentration obtained after temporarily dosing discontinuation or not matched with the following conditions were excluded from the analysis; Steady-state condition: at least 80% drug compliance from the previous visit to the day of sampling; Trough condition: samples taken within \u00b110% of 24 hours from last dosing.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline, Week 4, and Week 8", "groups": [{"id": "OG000", "title": "Baseline", "description": "After once daily administration of amlodipine 5 mg for 8 weeks in the screening period"}, {"id": "OG001", "title": "Week 4"}, {"id": "OG002", "title": "Week 8"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "145"}, {"groupId": "OG001", "value": "144"}, {"groupId": "OG002", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.18", "lowerLimit": "6.7", "upperLimit": "7.7"}, {"groupId": "OG001", "value": "16.9", "lowerLimit": "15.7", "upperLimit": "18.1"}, {"groupId": "OG002", "value": "16.9", "lowerLimit": "15.7", "upperLimit": "18.2"}]}]}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of \\<60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \\<12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer, Inc.", "email": "ClinicalTrials.govCallCenter@pfizer.com", "phone": "1-800-718-1021"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}